Haemonetics posts 2024-2025 responsibility report

Haemonetics Corporation filed a current report to inform investors that on February 12, 2026, it published its 2024-2025 Corporate Responsibility Report.

Rhea-AI Filing Summary

Haemonetics Corporation filed a current report to inform investors that on February 12, 2026, it published its 2024-2025 Corporate Responsibility Report. The report is available in the Corporate Responsibility section of the company’s website, highlighting its disclosure on environmental, social, and governance-related topics.

The company also clarifies that the information shared under this item is being furnished under Regulation FD rather than filed, meaning it is not subject to Section 18 liability of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Haemonetics (HAE) disclose in this 8-K filing?

Haemonetics disclosed that it published its 2024-2025 Corporate Responsibility Report on February 12, 2026. The report is accessible through the Corporate Responsibility section of its website and is being furnished under Regulation FD, not treated as filed under the Exchange Act.

Where can investors find Haemonetics (HAE) 2024-2025 Corporate Responsibility Report?

The 2024-2025 Corporate Responsibility Report is available on Haemonetics’ website in the Corporate Responsibility section. The 8-K notes that the report is published online and referenced for informational purposes under a Regulation FD disclosure item.

How is the Haemonetics (HAE) Corporate Responsibility Report treated under securities laws?

Haemonetics states the Corporate Responsibility Report is furnished under Regulation FD and not deemed filed under Section 18 of the Exchange Act. It is also not incorporated by reference into Securities Act or Exchange Act filings despite any general incorporation language elsewhere.

Does the Haemonetics (HAE) 8-K make the Corporate Responsibility Report part of other SEC filings?

No, the company explicitly states the Corporate Responsibility Report will not be deemed incorporated by reference into any Securities Act or Exchange Act filing. This applies even if those other filings contain general language about incorporating previously furnished information.

Who signed the Haemonetics (HAE) 8-K related to the Corporate Responsibility Report?

The 8-K was signed on behalf of Haemonetics Corporation by Christopher A. Simon, its President and Chief Executive Officer, dated February 12, 2026. This signature confirms the company’s authorization of the disclosure about the Corporate Responsibility Report publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:15 PM Learn about SEC filing dates

0000313143false00003131432026-02-122026-02-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2026

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

001-14041

04-2882273

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

125 Summer Street

Boston, MA 02110

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $.01 par value per share			HAE			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On February 12, 2026, Haemonetics Corporation (the “Company”) published its 2024-2025 Corporate Responsibility Report, which is accessible through the Corporate Responsibility section of the Company’s website.

The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

February 12, 2026

By:

/s/ Christopher A. Simon

Name:

Christopher A. Simon

Title:

President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB